Cantor Fitzgerald Maintains Overweight on Portage Biotech, Lowers Price Target to $11
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Li Watsek has maintained an Overweight rating on Portage Biotech (NASDAQ:PRTG) but lowered the price target from $16 to $11.
August 01, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Portage Biotech's price target has been lowered from $16 to $11 by Cantor Fitzgerald, though the Overweight rating is maintained.
The lowering of the price target by Cantor Fitzgerald could lead to a negative sentiment among investors, potentially causing a short-term decrease in the stock price. However, the maintained Overweight rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100